N
EGRX

Nuveen’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nuveen’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-42,118
Closed -$221K – 3448
2024
Q1 		$221K Sell
42,118
-130,731
-76% -$718K ﹤0.01% 3166
2023
Q4 		$904K Buy
172,849
+30,147
+21% +$298K ﹤0.01% 2781
2023
Q3 		$2.25M Buy
142,702
+76,565
+116% +$1.38M ﹤0.01% 2254
2023
Q2 		$1.29M Sell
66,137
-24,685
-27% -$586K ﹤0.01% 2546
2023
Q1 		$2.58M Buy
90,822
+12,890
+17% +$383K ﹤0.01% 2237
2022
Q4 		$2.28M Buy
77,932
+13,013
+20% +$414K ﹤0.01% 2332
2022
Q3 		$1.72M Sell
64,919
-2,976
-4% -$109K ﹤0.01% 2478
2022
Q2 		$3.02M Buy
67,895
+25,859
+62% +$1.19M ﹤0.01% 2224
2022
Q1 		$2.06M Buy
42,036
+414
+1% +$19.9K ﹤0.01% 2490
2021
Q4 		$1.91M Sell
41,622
-6,026
-13% -$312K ﹤0.01% 2586
2021
Q3 		$2.66M Sell
47,648
-936
-2% -$46.1K ﹤0.01% 2539
2021
Q2 		$2.08M Sell
48,584
-4,159
-8% -$172K ﹤0.01% 2691
2021
Q1 		$2.2M Buy
52,743
+1,267
+2% +$58.8K ﹤0.01% 2575
2020
Q4 		$2.4M Buy
51,476
+1,795
+4% +$84K ﹤0.01% 2418
2020
Q3 		$2.11M Sell
49,681
-911
-2% -$39.9K ﹤0.01% 2357
2020
Q2 		$2.43M Buy
50,592
+6,276
+14% +$313K ﹤0.01% 2253
2020
Q1 		$2.04M Buy
44,316
+1,111
+3% +$55.8K ﹤0.01% 2176
2019
Q4 		$2.6M Sell
43,205
-533
-1% -$31.8K ﹤0.01% 2319
2019
Q3 		$2.47M Sell
43,738
-330
-0.7% -$18.6K ﹤0.01% 2312
2019
Q2 		$2.45M Buy
+44,068
New +$2.3M ﹤0.01% 2341

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's EGRX Position: Q2 2024 in Review

Nuveen sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 42,118 shares — an estimated $221K sold.

Nuveen first reported a position in EGRX in Q2 2019 and held it in 20 quarters. The position peaked at $3.02M in Q2 2022. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Nuveen reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 42,118 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $221K.
  • Nuveen first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 20 quarters.
  • Nuveen's Eagle Pharmaceuticals, Inc. position peaked at $3.02M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.